Skip to main content
Top
Published in: BMC Public Health 1/2024

Open Access 01-12-2024 | Mycobacterium Tuberculosis | Research

Immune Dysregulation in SARS-CoV-2 patients coinfected with Mycobacterium tuberculosis (Mtb) or HIV in China

Authors: Lei Li, Jianxiang Zhang, Ranran Sun, Hong Liu, Genyang Cheng, Feifei Fan, Chong Wang, Ang Li, Hongxia Liang, Zujiang Yu, Guiqiang Wang, Zhigang Ren

Published in: BMC Public Health | Issue 1/2024

Login to get access

Abstract

Background

SARS-CoV-2 infections usually cause immune dysregulation in the human body. Studies of immunological changes resulting from coinfections with Mycobacterium tuberculosis (Mtb) or HIV are limited.

Methods

We conducted a retrospective study focusing on patients with COVID-19. A total of 550 patients infected with SARS-CoV-2 were enrolled in our study and categorized into four groups based on the presence of coinfections; 166 Delta-infected patients, among whom 103 patients had no coinfections, 52 who were coinfected with Mtb, 11 who were coinfected with HIV, and 384 Omicron-infected patients. By collecting data on epidemiologic information, laboratory findings, treatments, and clinical outcomes, we analyzed and compared clinical and immunological characteristics.

Results

Compared with those in the Delta group, the median white blood cell, CD4 + T-cell and B-cell counts were lower in the Mtb group and the HIV group. Except for those in the Omicron group, more than half of the patients in the three groups had abnormal chest CT findings. Among the three groups, there were no significant differences in any of the cytokines. Compared with those in the Delta group, the disease duration and LOS were longer in the Mtb group and the HIV group. For unvaccinated Delta-infected patients, in the Mtb and HIV groups, the number of B cells and CD4 + T cells was lower than that in the Delta group, with no significant difference in the LOS or disease duration. In the Mtb group, three (6%) patients presented with a disease duration greater than four months and had decreased lymphocyte and IL17A counts, possibly due to double infections in the lungs caused by SARS-CoV-2 and M. tuberculosis.

Conclusions

We found that SARS-CoV-2 patients coinfected with Mtb or HIV exhibited a longer disease duration and longer LOS, with a decrease in B cells and CD4 + T cells, suggesting that these cells are related to immune function. Changes in cytokine levels suggest that coinfection with Mtb or HIV does not result in dysregulation of the immune response. Importantly, we discovered a chronic course of coinfection involving more than four months of Mtb and SARS-CoV-2 infection.
Appendix
Available only for authorised users
Literature
2.
go back to reference Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le Guen J, Kassis-Chikhani N, Edriss D, Belec L, Seve A, Courtellemont L, Pere H, Hocqueloux L, Fafi-Kremer S, Prazuck T, Mouquet H, Bruel T, Simon-Loriere E, Rey FA, Schwartz O. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276–.ADSCrossRefPubMed Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le Guen J, Kassis-Chikhani N, Edriss D, Belec L, Seve A, Courtellemont L, Pere H, Hocqueloux L, Fafi-Kremer S, Prazuck T, Mouquet H, Bruel T, Simon-Loriere E, Rey FA, Schwartz O. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276–.ADSCrossRefPubMed
3.
go back to reference McCallum M, Walls AC, Sprouse KR, Bowen JE, Rosen L, Dang H, DeMarco A, Franko N, Tilles SW, Logue J, Miranda MC, Ahlrichs M, Carter L, Snell G, Pizzuto MS, Chu HY, Van Voorhis WC, Corti D, Veesler D. Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. Science. 2021;374:1621.ADSCrossRefPubMed McCallum M, Walls AC, Sprouse KR, Bowen JE, Rosen L, Dang H, DeMarco A, Franko N, Tilles SW, Logue J, Miranda MC, Ahlrichs M, Carter L, Snell G, Pizzuto MS, Chu HY, Van Voorhis WC, Corti D, Veesler D. Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. Science. 2021;374:1621.ADSCrossRefPubMed
4.
go back to reference Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang BB, Tuekprakhon A, Nutalai R, Zhou DM, Mentzer AJ, Zhao YG, Duyvesteyn HME, Lopez-Camacho C, Slon-Campos J, Walter TS, Skelly D, Johnson SA, Ritter TG, Mason C, Clemens SAC, Naveca FG, Nascimento V, Nascimento F, da Costa CF, Resende PC, Pauvolid-Correa A, Siqueira MM, Dold C, Temperton N, Dong T, Pollard AJ, Knight JC, Crook D, Lambe T, Clutterbuck E, Bibi S, Flaxman A, Bittaye M, Belij-Rammerstorfer S, Gilbert SC, Malik T, Carroll MW, Klenerman P, Barnes E, Dunachie SJ, Baillie V, Serafin N, Ditse Z, Da Silva K, Paterson NG, Williams MA, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184:4220–.CrossRefPubMedPubMedCentral Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang BB, Tuekprakhon A, Nutalai R, Zhou DM, Mentzer AJ, Zhao YG, Duyvesteyn HME, Lopez-Camacho C, Slon-Campos J, Walter TS, Skelly D, Johnson SA, Ritter TG, Mason C, Clemens SAC, Naveca FG, Nascimento V, Nascimento F, da Costa CF, Resende PC, Pauvolid-Correa A, Siqueira MM, Dold C, Temperton N, Dong T, Pollard AJ, Knight JC, Crook D, Lambe T, Clutterbuck E, Bibi S, Flaxman A, Bittaye M, Belij-Rammerstorfer S, Gilbert SC, Malik T, Carroll MW, Klenerman P, Barnes E, Dunachie SJ, Baillie V, Serafin N, Ditse Z, Da Silva K, Paterson NG, Williams MA, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184:4220–.CrossRefPubMedPubMedCentral
5.
go back to reference Wang YP, Chen RC, Hu FY, Lan Y, Yang ZW, Zhan C, Shi JR, Deng XZ, Jiang M, Zhong SX, Liao BL, Deng K, Tang JY, Guo LL, Jiang ML, Fan QH, Li MY, Liu JX, Shi YL, Deng XL, Xiao XC, Kang M, Li Y, Guan WJ, Li YM, Li SY, Li F, Zhong NS, Tang XP. 2021. Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. Eclinicalmedicine 40. Wang YP, Chen RC, Hu FY, Lan Y, Yang ZW, Zhan C, Shi JR, Deng XZ, Jiang M, Zhong SX, Liao BL, Deng K, Tang JY, Guo LL, Jiang ML, Fan QH, Li MY, Liu JX, Shi YL, Deng XL, Xiao XC, Kang M, Li Y, Guan WJ, Li YM, Li SY, Li F, Zhong NS, Tang XP. 2021. Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. Eclinicalmedicine 40.
6.
go back to reference Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron Wave compared with previous waves. Jama-Journal of the American Medical Association. 2022;327:583–4.CrossRef Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron Wave compared with previous waves. Jama-Journal of the American Medical Association. 2022;327:583–4.CrossRef
7.
go back to reference Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, Amoako DG, Everatt J, Bhiman JN, Scheepers C, Tebeila N, Chiwandire N, du Plessis M, Govender N, Ismail A, Glass A, Mlisana K, Stevens W, Treurnicht FK, Makatini Z, Hsiao N-Y, Parboosing R, Wadula J, Hussey H, Davies M-A, Boulle A, von Gottberg A, Cohen C. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022;399:437–46.CrossRefPubMedPubMedCentral Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, Amoako DG, Everatt J, Bhiman JN, Scheepers C, Tebeila N, Chiwandire N, du Plessis M, Govender N, Ismail A, Glass A, Mlisana K, Stevens W, Treurnicht FK, Makatini Z, Hsiao N-Y, Parboosing R, Wadula J, Hussey H, Davies M-A, Boulle A, von Gottberg A, Cohen C. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022;399:437–46.CrossRefPubMedPubMedCentral
8.
go back to reference Osmanov IM, Spiridonova E, Bobkova P, Gamirova A, Shikhaleva A, Andreeva M, Blyuss O, El-Taravi Y, DunnGalvin A, Comberiati P, Peroni DG, Apfelbacher C, Genuneit J, Mazankova L, Miroshina A, Chistyakova E, Samitova E, Borzakova S, Bondarenko E, Korsunskiy AA, Konova I, Hanson SW, Carson G, Sigfrid L, Scott JT, Greenhawt M, Whittaker EA, Garralda E, Swann OV, Buonsenso D, Nicholls DE, Simpson F, Jones C, Semple MG, Warner JO, Vos T, Olliaro P, Munblit D, Sechenov Stop CRT. 2022. Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study. Eur Respir J 59. Osmanov IM, Spiridonova E, Bobkova P, Gamirova A, Shikhaleva A, Andreeva M, Blyuss O, El-Taravi Y, DunnGalvin A, Comberiati P, Peroni DG, Apfelbacher C, Genuneit J, Mazankova L, Miroshina A, Chistyakova E, Samitova E, Borzakova S, Bondarenko E, Korsunskiy AA, Konova I, Hanson SW, Carson G, Sigfrid L, Scott JT, Greenhawt M, Whittaker EA, Garralda E, Swann OV, Buonsenso D, Nicholls DE, Simpson F, Jones C, Semple MG, Warner JO, Vos T, Olliaro P, Munblit D, Sechenov Stop CRT. 2022. Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study. Eur Respir J 59.
10.
go back to reference Farheen S, Araf Y, Tang Y-D, Zheng C. The Deltacron conundrum: its origin and potential health risks. J Med Virol. 2022;94:5096–102.CrossRefPubMed Farheen S, Araf Y, Tang Y-D, Zheng C. The Deltacron conundrum: its origin and potential health risks. J Med Virol. 2022;94:5096–102.CrossRefPubMed
11.
go back to reference Langerbeins P, Hallek M. 2022. COVID-19 in patients with hematologic malignancy. Blood. Langerbeins P, Hallek M. 2022. COVID-19 in patients with hematologic malignancy. Blood.
12.
go back to reference Shariq M, Sheikh JA, Quadir N, Sharma N, Hasnain SE, Ehtesham NZ. 2022. COVID-19 and tuberculosis: the double whammy of respiratory pathogens. Eur Respiratory Rev 31. Shariq M, Sheikh JA, Quadir N, Sharma N, Hasnain SE, Ehtesham NZ. 2022. COVID-19 and tuberculosis: the double whammy of respiratory pathogens. Eur Respiratory Rev 31.
14.
go back to reference Sheikh A, McMenamin J, Taylor B, Robertson C, Public Hlth S, Collaborators EI. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397:2461–2.CrossRefPubMedPubMedCentral Sheikh A, McMenamin J, Taylor B, Robertson C, Public Hlth S, Collaborators EI. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397:2461–2.CrossRefPubMedPubMedCentral
15.
go back to reference Ma X, Li A, Jiao M, Shi Q, An X, Feng Y, Xing L, Liang H, Chen J, Li H, Li J, Ren Z, Sun R, Cui G, Zhou Y, Cheng M, Jiao P, Wang Y, Xing J, Shen S, Zhang Q, Xu A, Yu Z. 2020. Characteristic of 523 COVID-19 in Henan Province and a death prediction model. Frontiers in Public Health 8. Ma X, Li A, Jiao M, Shi Q, An X, Feng Y, Xing L, Liang H, Chen J, Li H, Li J, Ren Z, Sun R, Cui G, Zhou Y, Cheng M, Jiao P, Wang Y, Xing J, Shen S, Zhang Q, Xu A, Yu Z. 2020. Characteristic of 523 COVID-19 in Henan Province and a death prediction model. Frontiers in Public Health 8.
16.
go back to reference Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497–506.CrossRef Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497–506.CrossRef
17.
go back to reference Long L, Zeng XS, Zhang X, Xiao W, Guo E, Zhan WZ, Yang XJ, Li CY, Wu CY, Xu TT, Zhan C, Chen YH, Jiang M, Zhong NS, Lai KF. 2020. Short-term outcomes of COVID-19 and risk factors for progression. Eur Respir J 55. Long L, Zeng XS, Zhang X, Xiao W, Guo E, Zhan WZ, Yang XJ, Li CY, Wu CY, Xu TT, Zhan C, Chen YH, Jiang M, Zhong NS, Lai KF. 2020. Short-term outcomes of COVID-19 and risk factors for progression. Eur Respir J 55.
18.
go back to reference Zheng MJ, Gao Y, Wang G, Song GB, Liu SY, Sun DD, Xu YH, Tian ZG. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17:533–5.CrossRefPubMedPubMedCentral Zheng MJ, Gao Y, Wang G, Song GB, Liu SY, Sun DD, Xu YH, Tian ZG. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17:533–5.CrossRefPubMedPubMedCentral
19.
go back to reference Weigang S, Fuchs J, Zimmer G, Schnepf D, Kern L, Beer J, Luxenburger H, Ankerhold J, Falcone V, Kemming J, Hofmann M, Thimme R, Neumann-Haefelin C, Ulferts S, Grosse R, Hornuss D, Tanriver Y, Rieg S, Wagner D, Huzly D, Schwemmle M, Panning M, Kochs G. 2021. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants. Nat Commun 12. Weigang S, Fuchs J, Zimmer G, Schnepf D, Kern L, Beer J, Luxenburger H, Ankerhold J, Falcone V, Kemming J, Hofmann M, Thimme R, Neumann-Haefelin C, Ulferts S, Grosse R, Hornuss D, Tanriver Y, Rieg S, Wagner D, Huzly D, Schwemmle M, Panning M, Kochs G. 2021. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants. Nat Commun 12.
20.
go back to reference Hoffman SA, Costales C, Sahoo MK, Palanisamy S, Yamamoto F, Huang C, Verghese M, Solis DA, Sibai M, Subramanian A, Tompkins LS, Grant P, Shafer RW, Pinsky BA. SARS-CoV-2 neutralization resistance mutations in patient with HIV/AIDS, California, USA. Emerg Infect Dis. 2021;27:2720–3.CrossRefPubMedPubMedCentral Hoffman SA, Costales C, Sahoo MK, Palanisamy S, Yamamoto F, Huang C, Verghese M, Solis DA, Sibai M, Subramanian A, Tompkins LS, Grant P, Shafer RW, Pinsky BA. SARS-CoV-2 neutralization resistance mutations in patient with HIV/AIDS, California, USA. Emerg Infect Dis. 2021;27:2720–3.CrossRefPubMedPubMedCentral
21.
22.
23.
go back to reference Pormohammad A, Ghorbani S, Khatami A, Razizadeh MH, Alborzi E, Zarei M, Idrovo J-P, Turner RJ. 2021. Comparison of influenza type A and B with COVID-19: a global systematic review and meta-analysis on clinical, laboratory and radiographic findings. Reviews in Medical Virology 31. Pormohammad A, Ghorbani S, Khatami A, Razizadeh MH, Alborzi E, Zarei M, Idrovo J-P, Turner RJ. 2021. Comparison of influenza type A and B with COVID-19: a global systematic review and meta-analysis on clinical, laboratory and radiographic findings. Reviews in Medical Virology 31.
24.
go back to reference Gao Y, Liu M, Chen Y, Shi S, Geng J, Tian J. Association between Tuberculosis and COVID-19 severity and mortality: a rapid systematic review and meta-analysis. J Med Virol. 2021;93:194–6.CrossRefPubMed Gao Y, Liu M, Chen Y, Shi S, Geng J, Tian J. Association between Tuberculosis and COVID-19 severity and mortality: a rapid systematic review and meta-analysis. J Med Virol. 2021;93:194–6.CrossRefPubMed
Metadata
Title
Immune Dysregulation in SARS-CoV-2 patients coinfected with Mycobacterium tuberculosis (Mtb) or HIV in China
Authors
Lei Li
Jianxiang Zhang
Ranran Sun
Hong Liu
Genyang Cheng
Feifei Fan
Chong Wang
Ang Li
Hongxia Liang
Zujiang Yu
Guiqiang Wang
Zhigang Ren
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2024
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-024-17905-3

Other articles of this Issue 1/2024

BMC Public Health 1/2024 Go to the issue